Back to Browse Journals » Drug Design, Development and Therapy » Volume 3

Troglitazone reverses the multiple drug resistance phenotype in cancer cells

Authors Gerald F Davies, Bernhard HJ Juurlink, Troy AA Harkness

Published 17 March 2009 Volume 2009:3 Pages 79—88


Review by Single-blind

Peer reviewer comments 5

Gerald F Davies1, Bernhard HJ Juurlink2, Troy AA Harkness1

1Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, Canada; 2College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia

Abstract: A major problem in treating cancer is the development of drug resistance. We previously demonstrated doxorubicin (DOX) resistance in K562 human leukemia cells that was associated with upregulation of glyoxalase 1 (GLO-1) and histone H3 expression. The thiazolidinedione troglitazone (TRG) downregulated GLO-1 expression and further upregulated histone H3 expression and post-translational modifications in these cells, leading to a regained sensitivity to DOX. Given the pleiotropic effects of epigenetic changes in cancer development, we hypothesized that TRG may downregulate the multiple drug resistance (MDR) phenotype in a variety of cancer cells. To test this, MCF7 human breast cancer cells and K562 cells were cultured in the presence of low-dose DOX to establish DOX-resistant cell lines (K562/DOX and MCF7/DOX). The MDR phenotype was confirmed by Western blot analysis of the 170 kDa P-glycoprotein (Pgp) drug efflux pump multiple drug resistance protein 1 (MDR-1), and the breast cancer resistance protein (BCRP). TRG markedly decreased expression of both MDR-1 and BCRP in these cells, resulting in sensitivity to DOX. Silencing of MDR-1 expression also sensitized MCF7/DOX cells to DOX. Use of the specific and irreversible peroxisome proliferator-activated receptor gamma (PPARγ) inhibitor GW9662 in the nanomolar range not only demonstrated that the action of TRG on MCF/DOX was PPARγ-independent, but indicated that PPARγ may play a role in the MDR phenotype, which is antagonized by TRG. We conclude that TRG is potentially a useful adjunct therapy in chemoresistant cancers.

Keywords: chemotherapy, doxorubicin, breast cancer resistance protein-1, multiple drug resistance, multiple drug resistance protein 1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

The IL-17A G-197A and IL-17F 7488T/C polymorphisms are associated with increased risk of cancer in Asians: a meta-analysis

Wang H, Zhang Y, Liu Z, Zhang Y, Zhao H, Du S

Drug Design, Development and Therapy 2015, 9:5159-5168

Published Date: 24 September 2015

Carcinogenic activity of PbS quantum dots screened using exosomal biomarkers secreted from HEK293 cells

Kim JH, Kim HR, Lee BR, Choi ES, In SI, Kim EJ

International Journal of Nanomedicine 2015, 10:5513-5528

Published Date: 31 August 2015

Dexamethasone intravitreal implant in the treatment of diabetic macular edema

Dugel PU, Bandello F, Loewenstein A

Clinical Ophthalmology 2015, 9:1321-1335

Published Date: 16 July 2015

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN

Drug Design, Development and Therapy 2015, 9:3325-3339

Published Date: 29 June 2015

Cataract surgery and methods of wound closure: a review

Matossian C, Makari S, Potvin R

Clinical Ophthalmology 2015, 9:921-928

Published Date: 22 May 2015

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

Hoggatt J, Tate TA, Pelus LM

International Journal of Nanomedicine 2015, 10:2647-2652

Published Date: 1 April 2015

Functional capacity, physical activity, and quality of life in hypoxemic patients with chronic obstructive pulmonary disease

Saglam M, Vardar-Yagli N, Savci S, Inal-Ince D, Calik-Kutukcu E, Arikan H, Coplu L

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:423-428

Published Date: 26 February 2015

Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations

Pacławski A, Szlęk J, Lau R, Jachowicz R, Mendyk A

International Journal of Nanomedicine 2015, 10:801-810

Published Date: 21 January 2015